Re-runs extraction for each period with period-end year from max(2023, current year − 2) through the current year, oldest first (up to three reporting years). This can take a long time.
Biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics.
Sector: Health care
US_ABBV
No intraday sparkline from the default exchange feed; Yahoo or day change may still appear below when available.
No price chart.
Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.
Shares: sec_companyfacts/1551152
| Period | Issues |
|---|---|
| 2023-03-31 Q1 | ✗Errors 2Warn 1 |
| 2023-06-30 Q2 | ✗Errors 1Warn 1 |
| 2023-09-30 Q3 | ✗Errors 1Warn 2 |
| 2023-12-31 FY | ✗Errors 1Warn 1 |
| 2024-03-31 Q1 | ✗Errors 2Warn 3 |
| 2024-06-30 Q2 | ⚠Warn 1 |
| 2024-09-30 Q3 | ⚠Warn 1 |
| 2024-12-31 FY | ✗Errors 1Warn 2 |
| 2025-03-31 Q1 | ✗Errors 1Warn 1 |
| 2025-06-30 Q2 | ✗Errors 1Warn 4 |
| 2025-09-30 Q3 | ✗Errors 2Warn 2 |
| 2025-12-31 FY | ✗Errors 2Warn 2 |
| 2026-03-31 Q1 | ✗Errors 2Warn 1 |
Monetary columns are in B USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.
| Date | Period | Status | RevenueB USD | Operating profitB USD | D&AB USD | EBITDAB USD | Net profitB USD | Operating CFB USD | Capex + M&AB USD | AssetsB USD | EquityB USD | ROE (annualized) | Net debtB USD | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Q1 2026 (3M) | OK | 15.0 y/y 12.4% | 4.0 y/y 6.9% | 1.9 y/y -5.1% | 5.9 y/y 2.7% | 0.7 y/y -46.0% | 3.8 | -0.3 | 136.5 y/y 0.2% | -6.7 y/y -568.7% | -56.0% | 55.1 | Link |
| 2025-12-31 | FY 2025 (12M) | OK | 16.6 y/y 10.0% | 4.5 y/y 405.0% | 1.9 y/y -10.1% | 6.5 y/y 899.4% | 1.8 y/y 8354.5% | 5.2 | -0.3 | 134.0 y/y -0.9% | -3.3 y/y -198.3% | -143.0% | 56.4 | Link |
| 2025-09-30 | Q3 2025 (3M) | OK | 15.8 y/y 9.1% | 1.9 y/y -50.3% | 2.1 y/y 0.0% | 4.0 y/y -32.5% | 0.2 y/y -88.1% | 7.0 | -0.4 | 133.9 y/y -6.6% | -2.6 y/y -143.8% | -17.6% | 61.1 | Link |
| 2025-06-30 | Q2 2025 (3M) | OK | 15.4 y/y 6.6% | 4.9 y/y 22.4% | 2.1 y/y 0.1% | 7.0 y/y 14.8% | 0.9 y/y -31.5% | 5.2 | -0.3 | 137.2 y/y -3.4% | -0.2 y/y -102.7% | 606.6% | 62.0 | Link |
| 2025-03-31 | Q1 2025 (3M) | OK | 13.3 y/y 8.4% | 3.7 y/y 33.4% | 2.0 y/y -1.7% | 5.8 y/y 18.5% | 1.3 y/y -6.1% | 1.6 | -0.4 | 136.2 y/y -8.5% | 1.4 y/y -82.3% | 216.8% | 60.9 | Link |
| 2024-12-31 | FY 2024 (12M) | OK | 15.1 y/y 5.6% | -1.5 y/y -146.6% | 2.1 y/y 2.5% | 0.6 y/y -87.7% | 0.0 y/y -102.7% | 7.0 | -0.3 | 135.2 y/y 0.3% | 3.3 y/y -67.9% | 91.4% | 55.0 | Link |
| 2024-09-30 | Q3 2024 (3M) | OK | 14.5 y/y 3.8% | 3.8 y/y 68.0% | 2.1 y/y -4.8% | 5.9 y/y 32.3% | 1.6 y/y -12.2% | 5.4 | -8.5 | 143.4 y/y 5.3% | 6.0 y/y -50.1% | 32.5% | 51.3 | Link |
| 2024-06-30 | Q2 2024 (3M) | OK | 14.5 y/y 4.3% | 4.0 y/y -11.4% | 2.1 y/y -9.0% | 6.1 y/y -10.6% | 1.4 y/y -32.3% | 2.3 | -0.2 | 141.9 y/y 4.9% | 6.8 y/y -47.3% | 74.1% | 44.9 | Link |
| 2024-03-31 | Q1 2024 (3M) | OK | 12.3 y/y 0.7% | 2.8 y/y 1.1% | 2.1 y/y -2.5% | 4.9 y/y -0.5% | 1.4 y/y 472.8% | 4.0 | -9.4 | 148.9 y/y 10.7% | 8.0 y/y -39.7% | 59.6% | 45.7 | Link |
| 2023-12-31 | FY 2023 (12M) | OK | 14.3 y/y — | 3.2 y/y — | 2.1 y/y — | 5.3 y/y — | 0.8 y/y — | 4.8 | -0.2 | 134.7 y/y — | 10.4 y/y — | 43.3% | 39.5 | Link |
| 2023-09-30 | Q3 2023 (3M) | OK | 13.9 y/y — | 2.3 y/y — | 2.2 y/y — | 4.5 y/y — | 1.8 y/y — | 7.6 | -0.2 | 136.2 y/y — | 12.1 y/y — | 19.0% | 42.3 | Link |
| 2023-06-30 | Q2 2023 (3M) | OK | 13.9 y/y — | 4.5 y/y — | 2.3 y/y — | 6.8 y/y — | 2.0 y/y — | 6.3 | -0.2 | 135.4 y/y — | 12.9 y/y — | 61.9% | 47.1 | Link |
| 2023-03-31 | Q1 2023 (3M) | OK | 12.2 y/y — | 2.8 y/y — | 2.1 y/y — | 4.9 y/y — | 0.2 y/y — | 4.2 | -0.2 | 134.5 y/y — | 13.3 y/y — | — | 52.6 | Link |
Quarterly values ($ mln)
Year-over-year change
Net debt / cash ($ mln)
Current 19.6x · 3-year average 18.3x
No dividend rows found for this issuer (checked: Yahoo Finance (ex-div)).
Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)